Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Luis Gutiérrez-Rojas
 -- 4158 2022-08-04 10:07:15 |
2 update references and layout
Amina Yu
 + 2 word(s) 4160 2022-08-04 10:35:16 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ortega, M.A.;  Fraile-Martínez, �.;  García-Montero, C.;  Alvarez-Mon, M.A.;  Lahera, G.;  Monserrat, J.;  Llavero-Valero, M.;  Gutiérrez-Rojas, L.;  Molina, R.;  Rodríguez-Jimenez, R.; et al. Prevention and Clinical Management of Major Depressive Disorder. Encyclopedia. Available online: https://encyclopedia.pub/entry/25838 (accessed on 21 December 2024).
Ortega MA,  Fraile-Martínez �,  García-Montero C,  Alvarez-Mon MA,  Lahera G,  Monserrat J, et al. Prevention and Clinical Management of Major Depressive Disorder. Encyclopedia. Available at: https://encyclopedia.pub/entry/25838. Accessed December 21, 2024.
Ortega, Miguel A., Óscar Fraile-Martínez, Cielo García-Montero, Miguel Angel Alvarez-Mon, Guillermo Lahera, Jorge Monserrat, Maria Llavero-Valero, Luis Gutiérrez-Rojas, Rosa Molina, Roberto Rodríguez-Jimenez, et al. "Prevention and Clinical Management of Major Depressive Disorder" Encyclopedia, https://encyclopedia.pub/entry/25838 (accessed December 21, 2024).
Ortega, M.A.,  Fraile-Martínez, �.,  García-Montero, C.,  Alvarez-Mon, M.A.,  Lahera, G.,  Monserrat, J.,  Llavero-Valero, M.,  Gutiérrez-Rojas, L.,  Molina, R.,  Rodríguez-Jimenez, R.,  Quintero, J., & Mon, M.A.D. (2022, August 04). Prevention and Clinical Management of Major Depressive Disorder. In Encyclopedia. https://encyclopedia.pub/entry/25838
Ortega, Miguel A., et al. "Prevention and Clinical Management of Major Depressive Disorder." Encyclopedia. Web. 04 August, 2022.
Prevention and Clinical Management of Major Depressive Disorder
Edit
This entry is adapted from the peer-reviewed paper 10.3390/nu14153099

Major Depressive Disorder (MDD) is a growing disabling condition affecting around 280 million people worldwide. This complex entity is the result of the interplay between biological, psychological, and sociocultural factors, and compelling evidence suggests that MDD can be considered a disease that occurs as a consequence of an evolutionary mismatch and unhealthy lifestyle habits. In this context, diet is one of the core pillars of health, influencing multiple biological processes in the brain and the entire body. It seems that there is a bidirectional relationship between MDD and malnutrition, and depressed individuals often lack certain critical nutrients along with an aberrant dietary pattern. Thus, dietary interventions are one of the most promising tools to explore in the field of MDD, as there are a specific group of nutrients (i.e., omega 3, vitamins, polyphenols, and caffeine), foods (fish, nuts, seeds fruits, vegetables, coffee/tea, and fermented products) or dietary supplements (such as S-adenosylmethionine, acetyl carnitine, creatine, amino acids and so on.

major depressive disorder (MDD) dietary interventions omega 3 polyunsaturated fatty acids

1. Major Depressive Disorder and Diet: What Is the Relationship?

1.1. A General Perspective of Major Depressive Disorder

Major Depressive Disorder (MDD) is a leading disabling condition highly representative in our society, affecting nearly 280 million people worldwide [1]. Currently, MDD is placed as the third cause of disability globally, just after headache and lower back pain; however, the World Health Organization (WHO) projects that by 2030, MDD will become the first cause of disability worldwide [2][3]. Nowadays, the growing prevalence and annual incidence affected by pandemic times of the coronavirus disease 2019 (COVID-19) has made us reconsider the importance of mental health. In fact, according to current data, there has been a rise of 53.2 million MDD cases globally, representing an increase of 27.6% during the course of this pandemic [4]. This condition affects people from all age ranges, sex, and cultures; although, being aged between 45 and 59, of the female sex, and from a high-income country are associated with a higher risk of suffering from MDD. In fact, prevalence is double in women than in men [5][6]. In addition, it seems that the distribution of MDD can be different across regions. Thus, the lifetime prevalence of MDD can vary between 2 and 21% with the highest rates in some European countries and the lowest in certain Asian countries [7].
The precise causes of this complex malady are not fully understood. It seems that MDD is the result of an interplay between genetic and environmental factors. The estimated role of genetics is about 37%; although, a single gene has not been identified as a causative factor of MDD [8]. Instead, it seems that the inheritance of MDD is polygenic, the exposure to different environmental factors in certain critical periods being equally required [9]. In this sense, early life stress (i.e., child abuse) is one of the most important environmental factors related to the development of MDD, leading to determinant changes in the brain structure and function [10]. Similarly, chronic stress and frequent episodes of acute stress are also related to the onset of MDD [11]. The presence of physical or mental comorbidities together with multiple social factors can be equally prominent contributors to those suffering from MDD. In this sense, ethnic minorities, marital status (separated/divorced), poor education and healthcare access/quality, neighborhood, built environment, intimate partner violence, and lower socioeconomic resources are the most important social determinants related to the onset of MDD [7][12][13].
From a medical perspective, MDD can be considered a quite heterogeneous entity. Following the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria, MDD is clinically diagnosed by the presence of at least one of the two main criteria—depressed mood or anhedonia (the inability to feel pleasure or loss of interest) and ≥ 4 secondary symptoms during a minimum period of 2 weeks [14]. Collectively, the secondary symptoms of MDD can be divided into somatic or non-somatic items. The former include sleep disturbances, appetite changes, poor concentration, fatigue, and psychomotor agitation/retardation, whereas non-somatic symptoms are related to psychobehavioral alterations such as feelings of worthless, and suicide thoughts [15] The severity of MDD is generally assessed by the use of the Hamilton Depression Rating Scale (HAM-D), based on the use of specific punctuation marks for different clinical parameters [16]. Thus, a rating scale between 0 and 7 is defined as no depression; 8 and 16 mild depression; 17 and 23 moderate depression; and ≥24 severe depression [17][18]. The clinical management of these patients can be different according to the severity. Hence, for patients with mild depression, physical activity, or non-medical treatments may be encouraged. However, for patients with moderate or severe depression, the use of antidepressants, alone or in combination with psychotherapy and psychoeducation, is generally the most frequent approach [19].
On the other hand, notwithstanding an important percentage of patients responding to the therapy received, approximately 30% of patients suffer from resistance, which is known as treatment-resistant depression, representing an important medical and socioeconomic challenge [20]. In addition, patients with severe depression often require more intervention visits, more months of antidepressant treatment, and more antidepressant trials, but they tend to present worse clinical outcomes [21]. In this context, the socioeconomic burden of MDD is notably high, and not only are direct costs derived from their clinical management, but also indirect costs related to their lack of productivity or work absence must be considered. In the United States alone, the economic burden of MDD was USD 326.2 billion between 2010 and 2018, with a substantial rise in the indirect costs during this period [22].
Therefore, MDD is a challenging and growing public health concern that has a devastating impact on the individuals who suffer from this condition and the entire society. It is imperative to find novel approaches that facilitate the prevention and clinical management of this neuropsychiatric disorder, and nutritional intervention may represent a promising key to achieve these objectives.

1.2. Nutritional Status of the Patient with MDD

Malnutrition in form of undernutrition, overnutrition, or an imbalance of specific nutrients is a global community concern [23]. In general, children suffer more frequently from undernutrition, whereas adults tend to present overnutrition, especially in low- or middle-income countries and the poor population [24]. Likewise, malnutrition is remarkably higher in elder subjects, particularly with specific nutrient deficiencies [25]. It seems that there is a bidirectional link between malnutrition and MDD. On the one hand, malnutrition can drive several biological changes that can lead to the onset and progression of MDD. On the other hand, MDD can drive to eating disorders and lifestyle behaviors that may promote malnutrition [26]. However, there is an important association between malnutrition and MDD that can be observed in these patients.
Nutritional questionnaires such as the Mini Nutritional Assessment (MNA) have been useful to understand the connection between both entities. MNA represents a useful tool for monitoring patients of any age who are at risk of malnutrition. In this sense, rating as “malnourished” or “at risk of malnutrition” is associated with a higher risk of MDD, especially in elder individuals [27][28]. Moreover, some studies have found that patients with MDD are more likely to be at risk of undernutrition rather than overnutrition [29].
Simultaneously, the introduction of anthropometric variables has also aided in further insights being gained into the relationship between malnutrition and MDD. For instance, higher median levels of body weight, waist circumference, hip circumference, and waist-to-hip ratio were found in patients with MDD [30]. In this line, the waist-to-hip ratio appears to be inversely related to suicidality and severity of depression in women with postnatal depression, denoting the relevance of anthropometric measures in the clinical management of MDD [31].
When combining biochemical plus anthropometric variables, some studies have found that women with MDD have higher triglyceride, aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine levels and lower high-density lipoprotein cholesterol (HDL-C), hematocrit, and red blood cell counts; while depressed men were more likely to have higher triglyceride levels, lower hematocrit, and BUN and, in general, they present with less height and weight than their control group [32]. Self-perception can also be different between women and men. Women are more prone to perceive their body as larger than it really is, whereas, in men, the perception is just the opposite, idealizing a larger body [33].
Regarding the lack or excessive intake of specific nutrients, it is common that patients with MDD have an aberrant distribution of macronutrients (carbohydrates, proteins, and fats) and a deficiency of critical micronutrients (vitamins and minerals). In this context, prior works have associated high consumption of carbohydrates and low intake of protein with MDD [34]. Refined carbohydrates are one of the most deleterious nutrients included in westernized diets, being associated with multiple disease conditions [35]. Likewise, a direct relationship between trans unsaturated fatty acids and depression risk has been demonstrated [36], and a high dietary intake of saturated fats is sufficient to promote depressive-like behaviors in animal models [37]. Conversely, low high-quality fat intake, such as omega 3 polyunsaturated fatty acids (ꞷ-3 PUFA), has been associated with a higher risk of MDD [38]. Thus, patients with MDD often present with an insufficient protein and high-quality fat intake and with overconsumption of refined carbohydrates and poor-quality fats. In this situation, deficiencies in multiple vitamins and minerals are importantly linked to MDD. Particularly, a low intake of vitamin D and from the B complex—prominently thiamine (B1), niacin (B3), pyridoxin (B6), folate (B9), and cyanocobalamin (B12)—are observed in patients with MDD [39][40] Regarding minerals, low calcium, magnesium, iron, and zinc consumption has been associated with MDD [41], whereas low potassium, phosphorus, and copper intake can also be related to depressive symptoms for women, but not for men [42].
Collectively, there is compelling evidence that patients with MDD are commonly malnourished, or at least at risk of malnutrition. Thus, as it will be subsequently discussed, patients with MDD can benefit from addressing their nutritional status, as these dietary changes may favorably influence the intricate biology of depression.

1.3. Biology of Depression: Is There a Role for Diet?

The numerous difficulties related to the clinical management of MDD may be a consequence of the complex pathophysiological signature of this neuropsychiatric condition. Traditionally, the most widely known biological mechanism implicated in the pathophysiology of MDD has been aberrant neurotransmitter functioning and, particularly, decreased monoamine levels. Monoamines are represented by serotonin, dopamine, and norepinephrine, acting in critical brain regions and mediating several perceptions and behaviors in the brain [43]. However, currently, it is widely accepted that monoamines only represent a single mechanism of a really intricate picture [44]. Apart from monoamines, abnormal functioning of other neurotransmitters, such as gamma-aminobutyric acid (GABA), glutamate, and acetylcholine, has been reported in patients with MDD [45]. The available literature also considers the relevance of altered neuropeptides in the pathophysiology of MDD, including galanin (GAL), cholecystokinin (CCK), neuropeptide Y (NPY), oxytocin (OXT), vasopressin (VP), neuropeptide S (NPS), and melanin-concentrating hormone (MCH) [46]. Likewise, alterations in the neuropeptide melatonin and circadian disruption are similarly reported in patients with MDD [47], collectively supporting that there are many neurotransmitters and neuropeptides that are not working properly in the brain of depressed patients.
Furthermore, impaired neurogenesis and neuroplasticity have also been observed in the brain of depressed patients, having been proposed as a major pathophysiological signature of MDD [48]. For instance, alterations in neurotrophic factors such as brain-derived neurotrophic factor (BDNF) or glial-derived neurotrophic factor (GDNF) are critically involved in these changes, affecting several cellular processes [49][50]. The aberrant neurogenesis and neuroplasticity are closely linked to the effects of psychological stress in the patient with MDD. In this sense, it is widely accepted that this condition is associated with severe dysfunction of the hypothalamus–pituitary–adrenal (HPA) axis, characterized by altered levels of cortisol and their regulators, cortisol release factor (CRF) and the adrenocorticotropin hormone (ACTH), entailing detrimental consequences for the brain and the entire organism [51].
Moreover, consistent damage to neuronal and glial cells has been described in the brain of patients with MDD, with an enhanced mitochondrial dysfunction, apoptosis, oxidative stress, and excitotoxicity [52][53] All these changes lead to structural, functional, and connectivity abnormalities in specific regions of the central nervous system (CNS), such as the hippocampus, amygdala, dorsomedial thalamus, dorsal and medial prefrontal cortex, the dorsal and ventral anterior cingulate cortex, the orbital frontal cortex, the insula, and the striatum and raphe nucleus [54], which ultimately are responsible for the behavioral and mood dysfunctions related to MDD.
Not only local, but also extra-brain affections are observed in the patient with MDD. The immune system is a pivotal player in the pathophysiology of this condition and an aberrant inflammatory response can be observed either in the brain (neuroinflammation), or at systemic levels [55][56][57][58]. Metabolic and endocrine alterations (insulin resistance, type 2 diabetes, obesity and so on) are closely related to immune dysfunction and can influence at the onset and development of MDD [59]. Indeed, an exacerbated inflammatory response frequently co-occurs with endocrine, neural, and psychiatric alterations such as in MDD, which is studied in the field of psychoneuroimmunoendocrinology, explaining the biological link between MDD and systemic diseases [60]. Moreover, gut dysbiosis and an altered microbiota–gut–brain (MGB) axis are tightly linked with inflammation and the above-mentioned mechanisms, also representing a potential etiopathogenic mechanism of MDD [61][62]. Thereby, the pathophysiology of MDD is undoubtedly complex, explaining the clinical and translational difficulties of this condition.
Diet has pleiotropic effects in the organism. Depending on the content of specific nutrients and foods, as well as the whole dietary context, they may promote health or facilitate the onset and progression of multiple pathological conditions [35]. In the field of MDD, an umbrella review using 28 meta-analyses has defined the potential of nutrients, foods, beverages, and dietary patterns in the amelioration or progression of MDD; although, the quality of evidence is still moderate or low [63]. This means that further studies are warranted before drawing any definitive conclusion about the potential of diet and MDD. Indeed, some authors have claimed that narrative reviews tend to overestimate the impact of diet as preventive or as adjunctive support in this field [64], and there is an agreement that is critical to be objective and put in context the promising but still inconclusive role of diet in MDD. What the evidence seems to indicate is that dietary interventions can aid in the alleviation of depressive symptoms, but most of these results have been obtained in patients without a clinical diagnosis of depression [65], so once again it should be understood that MDD is a complex and multifactorial disorder in which plenty biological, cultural, and psychosocial factors are interacting, being a huge challenge for healthcare professionals (Figure 1).
Nutrients 14 03099 g001 550
Figure 1. Lifestyle interventions such as dietary interventions suppose an opportunity for addressing multiple targets in the complex network of depression. MDD: Major Depressive Disorder; HPA: hypothalamic–pituitary–adrenal; CNS: central nervous system; MGB: microbiota–gut–brain; BDNF: brain-derived neurotrophic factor; GDNF: glial-derived neurotrophic factor. #/?: Aberrant gut brain crosstalk due to an impaired MGB axis.
One of the most plausible explanations for the high prevalence of MDD and its relationship with diet can be perceived from an evolutionary context. Following the words of Theodosius Dobzhansky, “nothing in the biological aspects of medicine makes sense except in the light of evolution”. Evolutionary-based approaches have brought great advances in the understanding and clinical management of MDD [66]. MDD can be considered a disease that emerged as the result of low physical activity levels, sleep and circadian disturbances, low exposure to sunlight, social isolation, poor contact with nature, and, of course, due to poor dietary patterns [67]. Thus, lifestyle interventions following this evolutionary background have led to notable improvements in physical and mental health, while aiding to prevent the onset of mood disorders [68]. Moreover, addressing the entire picture from an evolutionary perspective, in combination with antidepressants and/or psychosocial support, along with additional medical therapy, if needed, can bring maximum benefits to patients with MDD (Figure 1).

2. Translational Opportunities: Clinical Management of MDD through Diet

2.1. Foods and Nutrients of Interest

Many efforts have been placed to find potential foods and dietary supplements with antidepressant effects as well as to prevent the onset of depression. These foods contain a wide variety of nutrients that act synergically to exert their benefits. Many times, these effects are different than those played by the nutrient alone. This concept is defined under the term food matrix, having numerous consequences for the global effect of foods [69]. Dietary supplements consist of an isolated nutrient with some interesting properties and both foods and supplements with potential preventive and supportive antidepressant activity can be defined as nutraceuticals, a growing area of research in the field of MDD [70]. In the field and clinical management of MDD, it is equally important to limit or avoid the consumption of ultra-processed foods, sugar-sweetened drinks, alcohol, as well as red and processed meats consumption, as they increase the risk of suffering from MDD [63]. In this part, the focus is on different food sources and supplements with potential preventive and antidepressant effects.

2.2. Dietary Strategies to Implement in Patients with MDD

Not only specific nutrients and foods, but also the entire dietary context are important approaches to consider in the clinical management and prevention of MDD. Indeed, unhealthy dietary patterns clearly influence the development and aggravation of MDD. For instance, it is well-known that excessive ultra-processed food consumption in westernized and proinflammatory diets is associated with pro-depressant effects [71][72]. On the other hand, different dietary approaches have been emerging since the last century in order to improve depressive symptoms. Some of the best-known strategies studied to support the prevention and treatment of MDD include the Mediterranean diet (MDiet), low-carbohydrate diet (LCD), and plant-based diet (vegetarianism and veganism). Here, it must be understood that the type of dietary strategy is not the most important point to consider, but the adherence to a healthy dietary pattern and the inclusion of a wide variety of food and nutrients is what really matters.
The MDiet is a type of dietary pattern mainly characterized by a richness of highly complex carbohydrates in fiber (cereals, legumes, vegetables, and fruits), polyunsaturated fatty acids with antiatherogenic and anti-inflammatory properties (i.e., fish, extra virgin olive oil, and nuts), and a plethora of bioactive compounds with antioxidative properties such as flavonoids, phytosterols, terpenes, and polyphenols [35]. This strategy has been widely explored in the prevention and management of non-communicable diseases (NCDs), especially those associated with aging [73] In this sense, some authors have described the relevance of the MDiet and some of their most representative elements on a differential epigenetic profile, which may explain the benefits of this diet in different disorders [74]. MDD is an intricate and multifactorial disorder and different results have been obtained regarding the inclusion of the MDiet. Some of the most important studies regarding the role of the MDiet in the prevention of different NCDs are PREDIMED (Prevención con Dieta Mediterránea) trials. One study described that moderate fish and long-chain ꞷ-3 PUFA consumption integrated in an MDiet was associated with lower odds of depression in a U-shaped way [75]. Likewise, one systematic review and meta-analysis found that adherence to the MDiet was prominently related to a reduced incidence of depression [76]. More detailly, another meta-analysis also found benefits from high and moderate MDiet adherence with a reduced risk of depression. Nevertheless, the positive association of moderate adherence seemed to fade with age [77]. Despite these conclusions, there are also other systematic reviews and meta-analyses that have failed to find significant associations between high adherence to the MDiet and the risk of depression [76][78], suggesting promising but still inconsistent evidence of the benefits of the MDiet in the prevention of depression. In the context of clinical management of patients with MDD, the SMILES (Supporting the Modification of lifestyle in Lowered Emotional States) trial should be highlighted. A total of 67 individuals were studied, 33 with a modified MDiet intervention and 34 without any nutritional but social support. Of them, 55 were also receiving some type of therapy, pharmacology, psychotherapy, or a combination of both. A total of 31 of the dietary support group and 25 of the controls completed the study at 12 weeks and after further analysis, the study concluded that this type of nutritional intervention helped in the clinical management of MDD, measured with the Montgomery–Åsberg Depression Rating Scale (MADRS) [79]. The dietary protocol for these patients is described in [80]. Extra virgin olive oil (EVOO), one of the most representative elements of the MDiet has recently proven antidepressant effects in patients with severe MDD, but not in those with mild to moderate [81]. All in all, the growing number of studies focusing on the preventive and therapeutic support of the MDiet has opened an interesting field of research. Further efforts are warranted to unravel the mechanisms and optimum protocols to obtain the greatest benefits from this type of dietary intervention.
LCDs such as the ketogenic or Atkins diet are mainly characterized by a reduced carbohydrate and high fat intake. Both aim to induce nutritional ketosis, and previous studies have found some evidence from the use of these strategies in the prevention and treatment of some neurological disorders such as epilepsy or Alzheimer’s disease [82]. Ketone bodies are not only a fat-derived energy supply, but they also exert important epigenetic functions, especially through histone post-translational modifications [83]. To date, there is some evidence of the antidepressant actions of ketone bodies in preclinical studies, case reports, and case series, but no clinical trials have been conducted in this field [84]. The benefits seem to be related to their regulatory role on different neurotransmitter levels, mitigating oxidative stress, insulin dysfunction, and inflammation, while favoring mitochondrial function and neurotrophic factors [84]. A negative point of following an LCD, however, may be related to negative long-term effects, as some authors have hypothesized that LCDs can induce metabolic depression, linked to reduced glycogen stores, and increased feelings of fatigue [85]. Likewise, combining this kind of strategy with intermittent fasting can exert synergic effects in the amelioration or prevention of depressive symptoms, sharing some similarities with an evolutionary or Paleolithic lifestyle; although, there are no clinical studies conducted with intermittent fasting in psychiatric populations yet [86][87]. Further efforts are required in this area before establishing the adequacy of this dietary context in MDD.
Plant-based diets also have different dietary patterns that have gained popularity in the last years, mainly aiming to reduce the environmental footprint of the diet and promote human health and animal welfare [88]. In general terms, plant-based diets are prominently represented by non-animal products; although, there is a broad spectrum of possibilities: including low meat but all food items (omnivore), all except meat (pesco-vegetarian), all except meat and fish (ovo-lacto-vegetarian), or plant-based items (vegan). Despite some evidence arising regarding the actions of a plant-based diet in the brain, the benefits and underlying mechanisms remain to be explored [89]. In this line, a possible epigenetic role of different bioactive components found in plants, especially by modulating DNA methylation, has been described [90]. There is some evidence that vegetarians/vegans may be at a higher risk of suffering from depression [91][92]. It is inconclusive if these associations can be mediated by a proper diet or if the vegans/vegetarians’ dietary pattern is a result of an increased susceptibility to depression. A potential explanation for this fact is that the vegetarian/vegan diet may not be properly balanced, being associated with the lack of some critical dietary components [93]. However, some authors argue that when well-designed and supplemented with vitamin B12, plant-based diets could bring potential benefits for overall health [94]. Once again, the quality of the diet may be a determinant factor. A cross-sectional study provided evidence that high-quality plant-based products (avoiding ultra-processed products and ensuring an adequate intake of different nutrients) can be protective for vegans/vegetarians without depression; although, individuals affected by depression did not show that benefit [95]. Similarly, avoiding the consumption of animal-based products such as meat, eggs, or dairy products did not show an improvement in mental health or MDD, according to some studies and meta-analyses [96][97]. This is attributed to the fact that these natural foods are rich in the different above-mentioned nutrients with potential benefits for the body [98]; although, vegetarianism/veganism if properly balanced, is also a laudable choice. Overall, it must be added that the actual studies in this area are quite heterogeneous. Currently, for patients with MDD, it seems that limiting or avoiding animal products may not be the appropriate approach. However, further research is needed, especially on well-designed and balanced vegetarian/vegan diets, before any final conclusions can be drawn.
Collectively, different studies regarding the implementation of a dietary pattern to prevent and ameliorate depression have been conducted. The MDiet has been the most widely studied strategy, providing many promising results; although, the level of evidence of its benefits is still insufficient. There are few studies on LCDs in depression; although, they may have some short-term benefits from depression due to the multiple regulatory benefits of ketone bodies. Finally, it seems that there is a negative association between a plant-based diet and depression; however, there is great heterogeneity. Moreover, it is not well-understood if vegetarianism/veganism can be a consequence of, or contributes to, some pathophysiological mechanisms. The most important points to consider are both the adherence to a healthy dietary pattern and, more prominently, the inclusion of high-quality foods, avoiding ultra-processed products, and ensuring a complete nutritional content, which will bring the most benefits for the prevention and, in an adequate context, for the clinical management of MDD.

References

  1. World Health Organization. Depression. Available online: https://www.who.int/news-room/fact-sheets/detail/depression (accessed on 20 July 2022).
  2. James, S.L.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858.
  3. Ortega, M.A.; Alvarez-Mon, M.A.; García-Montero, C.; Fraile-Martinez, O.; Lahera, G.; Monserrat, J.; Muñoz-Merida, L.; Mora, F.; Rodríguez-Jiménez, R.; Fernandez-Rojo, S.; et al. MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective. Biomedicines 2021, 9, 1659.
  4. Santomauro, D.F.; Herrera, A.M.M.; Shadid, J.; Zheng, P.; Ashbaugh, C.; Pigott, D.M.; Abbafati, C.; Adolph, C.; Amlag, J.O.; Aravkin, A.Y.; et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021, 398, 1700–1712.
  5. de la Torre, J.A.; Vilagut, G.; Ronaldson, A.; Dregan, A.; Ricci-Cabello, I.; Hatch, S.L.; Serrano-Blanco, A.; Valderas, J.M.; Hotopf, M.; Alonso, J. Prevalence and age patterns of depression in the United Kingdom. A population-based study. J. Affect. Disord. 2021, 279, 164–172.
  6. Kessler, R.C.; Bromet, E.J. The Epidemiology of Depression Across Cultures. Annu. Rev. Public Health 2013, 34, 119–138.
  7. Gutiérrez-Rojas, L.; Porras-Segovia, A.; Dunne, H.; Andrade-González, N.; Cervilla, J.A. Prevalence and correlates of major depressive disorder: A systematic review. Rev. Bras. Psiquiatr. 2020, 42, 657.
  8. Mullins, N.; Lewis, C. Genetics of Depression: Progress at Last. Curr. Psychiatry Rep. 2017, 19, 43.
  9. Saveanu, R.V.; Nemeroff, C.B. Etiology of Depression: Genetic and Environmental Factors. Psychiatr. Clin. North Am. 2012, 35, 51–71.
  10. Saleh, A.; Potter, G.G.; McQuoid, D.R.; Boyd, B.; Turner, R.; MacFall, J.R.; Taylor, W.D. Effects of early life stress on depression, cognitive performance and brain morphology. Psychol. Med. 2017, 47, 171.
  11. Hammen, C.; Kim, E.Y.; Eberhart, N.K.; Brennan, P.A. Chronic and acute stress and the prediction of major depression in women. Depress. Anxiety 2009, 26, 718–723.
  12. Yelton, B.; Friedman, D.B.; Noblet, S.; Lohman, M.C.; Arent, M.A.; Macauda, M.M.; Sakhuja, M.; Leith, K.H. Social Determinants of Health and Depression among African American Adults: A Scoping Review of Current Research. Int. J. Environ. Res. Public Health 2022, 19, 1498.
  13. Assari, S. Social Determinants of Depression: The Intersections of Race, Gender, and Socioeconomic Status. Brain Sci. 2017, 7, 156.
  14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Association: Arlington, TX, USA, 2013.
  15. Tolentino, J.C.; Schmidt, S.L. DSM-5 Criteria and Depression Severity: Implications for Clinical Practice. Front. Psychiatry 2018, 9, 450.
  16. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23, 56–62.
  17. Carrozzino, D.; Patierno, C.; Fava, G.A.; Guidi, J. The Hamilton Rating Scales for Depression: A Critical Review of Clinimetric Properties of Different Versions. Psychother. Psychosom. 2020, 89, 133–150.
  18. Zimmerman, M.; Martinez, J.H.; Young, D.; Chelminski, I.; Dalrymple, K. Severity classification on the Hamilton depression rating scale. J. Affect. Disord. 2013, 150, 384–388.
  19. Grover, S.; Gautam, S.; Jain, A.; Gautam, M.; Vahia, V.N. Clinical Practice Guidelines for the management of Depression. Indian J. Psychiatry 2017, 59, S34–S50.
  20. Voineskos, D.; Daskalakis, Z.J.; Blumberger, D.M. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr. Dis. Treat. 2020, 16, 221.
  21. Katon, W.; Unützer, J.; Russo, J. Major depression: The importance of clinical characteristics and treatment response to prognosis. Depress. Anxiety 2010, 27, 19–26.
  22. Greenberg, P.E.; Fournier, A.-A.; Sisitsky, T.; Simes, M.; Berman, R.; Koenigsberg, S.H.; Kessler, R.C. The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). Pharmacoeconomics 2021, 39, 653–665.
  23. Steiber, A.; Hegazi, R.; Herrera, M.; Zamor, M.L.; Chimanya, K.; Pekcan, A.G.; Redondo-Samin, D.C.D.; Correia, M.I.T.; Ojwang, A.A. Spotlight on Global Malnutrition: A Continuing Challenge in the 21st Century. J. Acad. Nutr. Diet. 2015, 115, 1335–1341.
  24. Perez-Escamilla, R.; Bermudez, O.; Buccini, G.S.; Kumanyika, S.; Lutter, C.; Monsivais, P.; Victora, C. Nutrition disparities and the global burden of malnutrition. BMJ 2018, 361, k2252.
  25. Norman, K.; Haß, U.; Pirlich, M. Malnutrition in Older Adults—Recent Advances and Remaining Challenges. Nutrients 2021, 13, 2764.
  26. Ortega, M.A.; Fraile-Martínez, Ó.; García-Montero, C.; Alvarez-Mon, M.A.; Lahera, G.; Monserrat, J.; Llavero-Valero, M.; Mora, F.; Rodríguez-Jiménez, R.; Fernandez-Rojo, S.; et al. Nutrition, Epigenetics, and Major Depressive Disorder: Understanding the Connection. Front. Nutr. 2022, 9, 867150.
  27. Alam, M.R.; Karmokar, S.; Reza, S.; Kabir, R.; Ghosh, S.; Al Mamun, A. Geriatric malnutrition and depression: Evidence from elderly home care population in Bangladesh. Prev. Med. Rep. 2021, 23, 101478.
  28. Velázquez-Alva, M.C.; Irigoyen-Camacho, M.E.; Cabrer-Rosales, M.F.; Lazarevich, I.; Arrieta-Cruz, I.; Gutiérrez-Juárez, R.; Zepeda-Zepeda, M.A. Prevalence of Malnutrition and Depression in Older Adults Living in Nursing Homes in Mexico City. Nutrients 2020, 12, 2429.
  29. Tsai, A.C.; Chou, Y.-T.; Chang, T.-L. Usefulness of the Mini Nutritional Assessment (MNA) in predicting the nutritional status of people with mental disorders in Taiwan. J. Clin. Nurs. 2011, 20, 341–350.
  30. Kaner, G.; Soylu, M.; Yüksel, N.; Inanç, N.; Ongan, D.; Başmısırlı, E. Evaluation of Nutritional Status of Patients with Depression. BioMed Res. Int. 2015, 2015, 521481.
  31. Nachane, H.B.; Nayak, A.S. Maternal anthropometric determinants as risk markers of suicidality and severity of illness in women with postnatal depression. J. Postgrad. Med. 2020, 66, 11–16.
  32. Lee, B.J. Association of depressive disorder with biochemical and anthropometric indices in adult men and women. Sci. Rep. 2021, 11, 13596.
  33. Silva, D.; Ferriani, L.; Viana, M.C. Depression, anthropometric parameters, and body image in adults: A systematic review. Rev. Assoc. Med. Bras. 2019, 65, 731–738.
  34. Oh, J.; Yun, K.; Chae, J.-H.; Kim, T.-S. Association Between Macronutrients Intake and Depression in the United States and South Korea. Front. Psychiatry 2020, 11, 207.
  35. García-Montero, C.; Fraile-Martínez, O.; Gómez-Lahoz, A.; Pekarek, L.; Castellanos, A.; Noguerales-Fraguas, F.; Coca, S.; Guijarro, L.; García-Honduvilla, N.; Asúnsolo, A.; et al. Nutritional Components in Western Diet Versus Mediterranean Diet at the Gut Microbiota–Immune System Interplay. Implications for Health and Disease. Nutrients 2021, 13, 699.
  36. Sánchez-Villegas, A.; Verberne, L.; De Irala, J.; Ruíz-Canela, M.; Toledo, E.; Serra-Majem, L.; Martínez-González, M.A. Dietary Fat Intake and the Risk of Depression: The SUN Project. PLoS ONE 2011, 6, e16268.
  37. Vagena, E.; Ryu, J.K.; Baeza-Raja, B.; Walsh, N.M.; Syme, C.; Day, J.P.; Houslay, M.D.; Baillie, G.S. A high-fat diet promotes depression-like behavior in mice by suppressing hypothalamic PKA signaling. Transl. Psychiatry 2019, 9, 141.
  38. Ciesielski, T.H.; Williams, S.M. Low Omega-3 intake is associated with high rates of depression and preterm birth on the country level. Sci. Rep. 2020, 10, 19749.
  39. Cuomo, A.; Giordano, N.; Goracci, A.; Fagiolini, A. Depression and Vitamin D Deficiency: Causality, Assessment, and Clinical Practice Implications. Neuropsychiatry 2017, 7, 606–614.
  40. Mikkelsen, K.; Stojanovska, L.; Apostolopoulos, V. The Effects of Vitamin B in Depression. Curr. Med. Chem. 2016, 23, 4317–4337.
  41. Miki, T.; Kochi, T.; Eguchi, M.; Kuwahara, K.; Tsuruoka, H.; Kurotani, K.; Ito, R.; Akter, S.; Kashino, I.; Pham, N.M.; et al. Dietary intake of minerals in relation to depressive symptoms in Japanese employees: The Furukawa Nutrition and Health Study. Nutrition 2015, 31, 686–690.
  42. Nguyen, T.T.T.; Miyagi, S.; Tsujiguchi, H.; Kambayashi, Y.; Hara, A.; Nakamura, H.; Suzuki, K.; Yamada, Y.; Shimizu, Y.; Nakamura, H. Association between Lower Intake of Minerals and Depressive Symptoms among Elderly Japanese Women but Not Men: Findings from Shika Study. Nutrients 2019, 11, 389.
  43. Azizi, S.A. Monoamines: Dopamine, Norepinephrine, and Serotonin, Beyond Modulation, “Switches” That Alter the State of Target Networks. Neuroscientist 2022, 28, 121–143.
  44. Hindmarch, I. Beyond the monoamine hypothesis: Mechanisms, molecules and methods. Eur. Psychiatry 2002, 17, 294–299.
  45. Pytka, K.; Dziubina, A.; Młyniec, K.; Dziedziczak, A.; Żmudzka, E.; Furgała, A.; Olczyk, A.; Sapa, J.; Filipek, B. The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. Pharmacol. Rep. 2016, 68, 443–450.
  46. Rana, T.; Behl, T.; Sehgal, A.; Singh, S.; Sharma, N.; Abdeen, A.; Ibrahim, S.F.; Mani, V.; Iqbal, M.S.; Bhatia, S.; et al. Exploring the role of neuropeptides in depression and anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry 2022, 114, 110478.
  47. Salva, M.A.Q.; Hartley, S.; Barbot, F.; Alvarez, J.C.; Lofaso, F.; Guilleminault, C. Circadian Rhythms, Melatonin and Depression. Curr. Pharm. Des. 2011, 17, 1459–1470.
  48. Bourin, M. Neurogenesis and Neuroplasticity in Major Depression: Its Therapeutic Implication. Adv. Exp. Med. Biol. 2021, 1305, 157–173.
  49. Castrén, E.; Monteggia, L.M. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biol. Psychiatry 2021, 90, 128–136.
  50. Zhang, Y.; Wang, L.; Wang, X.; Wang, Y.; Li, C.; Zhu, X. Alterations of DNA Methylation at GDNF Gene Promoter in the Ventral Tegmental Area of Adult Depression-Like Rats Induced by Maternal Deprivation. Front. Psychiatry 2019, 10, 732.
  51. Keller, J.; Gomez, R.; Williams, G.; Lembke, A.; Lazzeroni, L.; Murphy, G.M., Jr.; Schatzberg, A.F. HPA axis in major depression: Cortisol, clinical symptomatology and genetic variation predict cognition. Mol. Psychiatry 2017, 22, 527.
  52. Rajkowska, G.; Miguel-Hidalgo, J. Gliogenesis and Glial Pathology in Depression. CNS Neurol. Disord. Drug Targets 2007, 6, 219–233.
  53. Duman, R.S. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: Stress and depression. Dialog. Clin. Neurosci. 2009, 11, 239–255.
  54. Pandya, M.; Altinay, M.; Malone, D.A.; Anand, A. Where in the Brain Is Depression? Curr. Psychiatry Rep. 2012, 14, 634–642.
  55. Miller, A.H.; Raison, C.L. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2016, 16, 22.
  56. Alvarez-Mon, M.A.; Gómez, A.M.; Orozco, A.; Lahera, G.; Sosa, M.D.; Diaz, D.; Auba, E.; Albillos, A.; Monserrat, J.; Alvarez-Mon, M. Abnormal Distribution and Function of Circulating Monocytes and Enhanced Bacterial Translocation in Major Depressive Disorder. Front. Psychiatry 2019, 10, 812.
  57. Alvarez-Mon, M.; Gómez-Lahoz, A.; Orozco, A.; Lahera, G.; Diaz, D.; Ortega, M.; Albillos, A.; Quintero, J.; Aubá, E.; Monserrat, J.; et al. Expansion of CD4 T Lymphocytes Expressing Interleukin 17 and Tumor Necrosis Factor in Patients with Major Depressive Disorder. J. Pers. Med. 2021, 11, 220.
  58. Alvarez-Mon, M.A.; Gomez-Lahoz, A.M.; Orozco, A.; Lahera, G.; Sosa-Reina, M.D.; Diaz, D.; Albillos, A.; Quintero, J.; Molero, P.; Monserrat, J.; et al. Blunted Expansion of Regulatory T Lymphocytes Is Associated With Increased Bacterial Translocation in Patients With Major Depressive Disorder. Front. Psychiatry 2021, 11, 1530.
  59. Kahl, K.G. Metabolic alterations in patients with depression and their relationship to the etiology of depressive disorders. Ann. Gen. Psychiatry 2010, 9, S34.
  60. Francisco, V.; Gualillo, O.; van den Bossche, J.; Ortega, M.A.; García-Montero, C.; Fraile-Martinez, O.; Angel Alvarez-Mon, M.; Maria Gómez-Lahoz, A.; Lahera, G.; Monserrat, J.; et al. Immune-Mediated Diseases from the Point of View of Psychoneuroimmunoendocrinology. Biology 2022, 11, 973.
  61. Cepeda, M.S.; Katz, E.G.; Blacketer, C. Microbiome-Gut-Brain Axis: Probiotics and Their Association With Depression. J. Neuropsychiatry Clin. Neurosci. 2016, 29, 39–44.
  62. Ortega, M.A.; Alvarez-Mon, M.A.; García-Montero, C.; Fraile-Martinez, O.; Guijarro, L.G.; Lahera, G.; Monserrat, J.; Valls, P.; Mora, F.; Rodríguez-Jiménez, R.; et al. Gut Microbiota Metabolites in Major Depressive Disorder—Deep Insights into Their Pathophysiological Role and Potential Translational Applications. Metabolites 2022, 12, 50.
  63. Xu, Y.; Zeng, L.; Zou, K.; Shan, S.; Wang, X.; Xiong, J.; Zhao, L.; Zhang, L.; Cheng, G. Role of dietary factors in the prevention and treatment for depression: An umbrella review of meta-analyses of prospective studies. Transl. Psychiatry 2021, 11, 478.
  64. Thomas-Odenthal, F.; Molero, P.; Van Der Does, W.; Molendijk, M. Impact of review method on the conclusions of clinical reviews: A systematic review on dietary interventions in depression as a case in point. PLoS ONE 2020, 15, e0238131.
  65. Firth, J.; Marx, W.; Dash, S.; Carney, R.; Teasdale, S.; Solmi, M.; Stubbs, B.; Schuch, F.; Carvalho, A.F.; Jacka, F.; et al. The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials. Psychosom. Med. 2019, 81, 265–280.
  66. Hollon, S.D.; Andrews, P.W.; Thomson, J.A. Cognitive Behavior Therapy for Depression From an Evolutionary Perspective. Front. Psychiatry 2021, 12, 667592.
  67. Hidaka, B.H. Depression as a disease of modernity: Explanations for increasing prevalence. J. Affect. Disord. 2012, 140, 205–214.
  68. Durisko, Z.; Mulsant, B.H.; Mckenzie, K.; Andrews, P.W. Using Evolutionary Theory to Guide Mental Health Research. Can. J. Psychiatry 2016, 61, 159–165.
  69. Aguilera, J.M. The food matrix: Implications in processing, nutrition and health. Crit. Rev. Food Sci. Nutr. 2018, 59, 3612–3629.
  70. Alvarez-Mon, M.A.; Ortega, M.A.; García-Montero, C.; Fraile-Martinez, O.; Monserrat, J.; Lahera, G.; Mora, F.; Rodriguez-Quiroga, A.; Fernandez-Rojo, S.; Quintero, J.; et al. Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects. Pharmaceuticals 2021, 14, 821.
  71. Li, Y.; Lv, M.-R.; Wei, Y.-J.; Sun, L.; Zhang, J.-X.; Zhang, H.-G.; Li, B. Dietary patterns and depression risk: A meta-analysis. Psychiatry Res. 2017, 253, 373–382.
  72. Tolkien, K.; Bradburn, S.; Murgatroyd, C. An anti-inflammatory diet as a potential intervention for depressive disorders: A systematic review and meta-analysis. Clin. Nutr. 2019, 38, 2045–2052.
  73. Dominguez, L.; Di Bella, G.; Veronese, N.; Barbagallo, M. Impact of Mediterranean Diet on Chronic Non-Communicable Diseases and Longevity. Nutrients 2021, 13, 2028.
  74. Arpón, A.; Milagro, F.I.; Razquin, C.; Corella, D.; Estruch, R.; Fitó, M.; Marti, A.; Martínez-González, M.A.; Ros, E.; Salas-Salvadó, J.; et al. Impact of Consuming Extra-Virgin Olive Oil or Nuts within a Mediterranean Diet on DNA Methylation in Peripheral White Blood Cells within the PREDIMED-Navarra Randomized Controlled Trial: A Role for Dietary Lipids. Nutrients 2017, 10, 15.
  75. Sánchez-Villegas, A.; Álvarez-Pérez, J.; Toledo, E.; Salas-Salvadó, J.; Ortega-Azorín, C.; Zomeño, M.D.; Vioque, J.; Martínez, J.A.; Romaguera, D.; Pérez-López, J.; et al. Seafood Consumption, Omega-3 Fatty Acids Intake, and Life-Time Prevalence of Depression in the PREDIMED-Plus Trial. Nutrients 2018, 10, 2000.
  76. Shafiei, F.; Moghaddam, A.S.; Larijani, B.; Esmaillzadeh, A. Adherence to the Mediterranean diet and risk of depression: A systematic review and updated meta-analysis of observational studies. Nutr. Rev. 2019, 77, 230–239.
  77. Psaltopoulou, T.; Sergentanis, T.N.; Panagiotakos, D.B.; Sergentanis, I.N.; Kosti, R.; Scarmeas, N. Mediterranean diet, stroke, cognitive impairment, and depression: A meta-analysis. Ann. Neurol. 2013, 74, 580–591.
  78. Hershey, M.S.; Sanchez-Villegas, A.; Sotos-Prieto, M.; Fernandez-Montero, A.; Pano, O.; Lahortiga-Ramos, F.; Martínez-González, M.; Ruiz-Canela, M. The Mediterranean Lifestyle and the Risk of Depression in Middle-Aged Adults. J. Nutr. 2022, 152, 227–234.
  79. Jacka, F.N.; O’Neil, A.; Opie, R.; Itsiopoulos, C.; Cotton, S.; Mohebbi, M.; Castle, D.; Dash, S.; Mihalopoulos, C.; Chatterton, M.L.; et al. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Med. 2017, 15, 23.
  80. Opie, R.; O’Neil, A.; Jacka, F.N.; Pizzinga, J.; Itsiopoulos, C. A modified Mediterranean dietary intervention for adults with major depression: Dietary protocol and feasibility data from the SMILES trial. Nutr. Neurosci. 2018, 21, 487–501.
  81. Foshati, S.; Ghanizadeh, A.; Akhlaghi, M. Extra-Virgin Olive Oil Improves Depression Symptoms Without Affecting Salivary Cortisol and Brain-Derived Neurotrophic Factor in Patients with Major Depression: A Double-Blind Randomized Controlled Trial. J. Acad. Nutr. Diet. 2022, 122, 284–297.e1.
  82. Oh, R.; Gilani, B.; Uppaluri, K.R. Low Carbohydrate Diet. In StatPearls; StatPearls: Treasure Island, FL, USA, 2021.
  83. Dąbek, A.; Wojtala, M.; Pirola, L.; Balcerczyk, A. Modulation of Cellular Biochemistry, Epigenetics and Metabolomics by Ketone Bodies. Implications of the Ketogenic Diet in the Physiology of the Organism and Pathological States. Nutrients 2020, 12, 788.
  84. Brietzke, E.; Mansur, R.B.; Subramaniapillai, M.; Balanzá-Martínez, V.; Vinberg, M.; González-Pinto, A.; Rosenblat, J.D.; Ho, R.; McIntyre, R.S. Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neurosci. Biobehav. Rev. 2018, 94, 11–16.
  85. Winwood-Smith, H.S.; Franklin, C.E.; White, C.R. Low-carbohydrate diet induces metabolic depression: A possible mechanism to conserve glycogen. Am. J. Physiol. Integr. Comp. Physiol. 2017, 313, R347–R356.
  86. Igwe, O.; Sone, M.; Matveychuk, D.; Baker, G.B.; Dursun, S.M. A review of effects of calorie restriction and fasting with potential relevance to depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2021, 111, 110206.
  87. Berthelot, E.; Etchecopar-Etchart, D.; Thellier, D.; Lancon, C.; Boyer, L.; Fond, G. Fasting Interventions for Stress, Anxiety and Depressive Symptoms: A Systematic Review and Meta-Analysis. Nutrients 2021, 13, 3947.
  88. Alcorta, A.; Porta, A.; Tárrega, A.; Alvarez, M.D.; Pilar Vaquero, M. Foods for Plant-Based Diets: Challenges and Innovations. Foods 2021, 10, 293.
  89. Medawar, E.; Huhn, S.; Villringer, A.; Witte, A.V. The effects of plant-based diets on the body and the brain: A systematic review. Transl. Psychiatry 2019, 9, 226.
  90. Tiffon, C. The Impact of Nutrition and Environmental Epigenetics on Human Health and Disease. Int. J. Mol. Sci. 2018, 19, 3425.
  91. Iguacel, I.; Huybrechts, I.; Moreno, L.A.; Michels, N. Vegetarianism and veganism compared with mental health and cognitive outcomes: A systematic review and meta-analysis. Nutr. Rev. 2021, 79, 361–381.
  92. Ocklenburg, S.; Borawski, J. Vegetarian diet and depression scores: A meta-analysis. J. Affect. Disord. 2021, 294, 813–815.
  93. Guzek, D.; Gła¸bska, D.; Groele, B.; Gutkowska, K. Fruit and Vegetable Dietary Patterns and Mental Health in Women: A Systematic Review. Nutr. Rev. 2022, 80, 1357–1370.
  94. Barnard, N.D.; Leroy, F. Children and adults should avoid consuming animal products to reduce risk for chronic disease: YES. Am. J. Clin. Nutr. 2020, 112, 926–930.
  95. Lee, M.F.; Eather, R.; Best, T. Plant-based dietary quality and depressive symptoms in Australian vegans and vegetarians: A cross-sectional study. BMJ Nutr. Prev. Health 2021, 4, e000332.
  96. Sangsefidi, Z.S.; Mirzaei, M.; Hosseinzadeh, M. The relation between dietary intakes and psychological disorders in Iranian adults: A population-based study. BMC Psychiatry 2020, 20, 257.
  97. Dobersek, U.; Wy, G.; Adkins, J.; Altmeyer, S.; Krout, K.; Lavie, C.J.; Archer, E. Meat and mental health: A systematic review of meat abstention and depression, anxiety, and related phenomena. Crit. Rev. Food Sci. Nutr. 2021, 61, 622–635.
  98. Zhu, R.; Fogelholm, M.; Jalo, E.; Poppitt, S.D.; Silvestre, M.P.; Møller, G.; Huttunen-Lenz, M.; Stratton, G.; Sundvall, J.; Macdonald, I.A.; et al. Animal-based food choice and associations with long-term weight maintenance and metabolic health after a large and rapid weight loss: The PREVIEW study. Clin. Nutr. 2022, 41, 817–828.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Health Care Sciences & Services
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Miguel A. Ortega
,
Óscar Fraile-Martínez
,
Cielo García-Montero
,
Miguel Angel Alvarez-Mon
,
Guillermo Lahera
,
Jorge Monserrat
,
Maria Llavero-Valero
,
Luis Gutiérrez-Rojas
,
Rosa Molina
,
Roberto Rodríguez-Jimenez
,
Javier Quintero
,
Melchor Alvarez De Mon
View Times: 572
Revisions: 2 times (View History)
Update Date: 04 Aug 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback